Phase II Study of Dose-Adjusted EPOCH +/- Rituximab in Adults With Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma.

Prognostic Factors for Adult Burkitt Lymphoma Patients Treated with Dose-Adjusted EPOCH-R

R Lakhotia;K Dunleavy;J Abramson;B Link;B Powell;C Melani;N Lucas;S Steinberg;JW Friedberg;B Kahl;R Little;N Bartlett;A Noy;W Wilson;M Roschewski Blood Advances Jun 30;bloodadvances.2023010223. doi: 10.1182/bloodadvances.2023010223. Online ahead of print

PMid: PMID37389844

Prognostic Factors Other than Age Drive the Risk of Disease Progression in Adults with Burkitt Lymphoma Treated with DA-EPOCH-R

R Lakhotia;K Dunleavy;J Abramson;B Powell;B Link;P Patel;P Bierman;C Melani;A Lucas;S Steinberg;JW Friedberg;B Kahl;R Little;N Bartlett;M Fanale;A Noy;W Wilson;M Roschewski American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #453

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma

M Roschewski;K Dunleavy;JS Abramson;BL Powell;B Link;P Patel;PJ Bierman;D Jagadeesh;S Parekh;S Nagpal;TE O'Brien;R Mitsuyasu;D Peace;PR Watson;R Battini;W Hanna;C Melani;AN Lucas;SM Steinberg;S Pittaluga;ES Jaffe;JW Friedberg;BS Kahl;R Little;NL Bartlett;M Finale;A Noy;WH Wilson Journal of Clinical Oncology Aug 1;38(22):2519-2529; May 26;JCO2000303. doi: 10.1200/JCO.20.00303. Online ahead of print

PMid: PMID32453640 | PMC number: PMC7392744

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

KE Dunleavy;MA Fanale;JS Abramson;A Noy;P Fabrizio Caimi;S Pittaluga;S Parekh;A Lacasce;JW Hayslip;D Jagadeesh;S Nagpal;MJ Lechowicz;R Gaur;JW Leach;A Lucas;C Melani;M Roschewski;SM Steinberg;ES Jaffe;BS Kahl;JW Friedberg;RF Little;NL Bartlett;WH Wilson Lancet Haematology Dec;5(12):e609-e617

PMid: PMID30501868 | PMC number: PMC6342507

Risk-adapted therapy in adults with burkitt lymphoma: updated results of a multicenter prospective phase II study of DA-EPOCH-R

K Dunleavy;M Roschewski;JS Abramson;A LaCasce;B Link;S Parekh;D Jagadeesh;S Nagpal;P Bierman;R Mitsuyasu;R Battini;PR Watson;D Peace;B Averbrook;H Naina;JW Leach;W Hanna;B Powell;C Melani;A Lucas;SM Steinberg;B Kahl;JW Friedberg;RF Little;N Bartlett;M Fanale;A Noy;WH Wilson International Conference on Malignant Lymphoma (June 14-17, 2017, Lugano, Switzerland), oral presentation

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R

M Roschewski;K Dunleavy;J Abramson;B Link;S Parekh;D Jagadeesh;P Bierman;R Baattini;W Watson;D Peace;W Hanna;B Powell;T O'Brien;D King;C Melani;A Lucas;S Steinberg;B Kahl;J Friedberg;R Little;N Bartlett;M Fanale;A Noy;WH Wilson Blood 130:188;American Society of Hematology Annual Meeting (Dec 9-12, 2017, Atlanta, GA), oral

Risk-adapted low-intensity therapy in adults with Burkitt lymphoma: preliminary report of a multicenter prospective phase II study of DA-EPOCH-R

K Dunleavy;A LaCasce;B Link;S Parekh;D Jagadeesh;R Lord;P Bierman;R Mitsuyasu;R Battini;PR Watson;D Peace;BJ Averbrook;H Naina;JW Leach;W Hanna;B Powell;M Roschewski;A Lucas;SM Steinberg;B Kahl;J Friedberg;RF Little;NL Bartlett;M Fanale;WH Wilson Blood 126(23):342; American Society of Hematology Annual Meeting (Dec 5-8, Orlando, FL), oral;

Preliminary report of a multicenter prospective phase II study of DA-EPOCH-R in MYC-rearranged aggressive B-cell lymphoma

K Dunleavy;MA Fanale;A LaCasce;A Noy;P Fabrizio;S Parekh;JW Hayslip;AS Advani;RS Lord;MJ Lechowicz;R Gaur;JW Leach;A Lucas;S Steinberg;B Kahl;JW Friedberg;RF Little;N Bartlett;W Wilson Blood 124(21):395; American Society for Hematology (December 6-9, 2014, San Francisco, CA), oral;